Assertio Therapeutics, Inc.
100 South Saunders Road, Suite 300
About Assertio Therapeutics, Inc.
Assertio reflects an aspirational mindset that is forward thinking, energetic, and entrepreneurial in spirit. The Assertio mission of advancing patient care is reflected in our three-pillar strategy:
In December 2017, the Company announced the signing of a definitive Commercialization Agreement with Collegium Pharmaceutical under which Collegium will commercialize the NUCYNTA pain franchise and Assertio will receive a royalty rate on all NUCYNTA revenues based on certain net sales thresholds.
Our long-term strategy is to continue to identify, license, develop and market distinctive products that offer enhanced therapeutic options for patients in need—all while maintaining the highest ethical standards in all our business practices.
We have developed and are licensing Acuform® technology, a patented oral delivery technology that allows for targeted, extended release of compounds into the upper GI tract. Acuform is currently utilized in four marketed products, including NUCYNTA ER and Gralise. To date, we’ve also licensed Acuform to six partners
We currently market three FDA-approved products for various neurological conditions.
We have created a new specialty products business unit, with the objective of assembling a portfolio of specialty/orphan drugs that address the unmet needs of patients, physicians and payers. Our initial focus is the development of Cosyntropin (synthetic ACTH depot), a unique, late-stage product that, upon approval, will provide U.S. patients, physicians and payers with an alternative option.
12 articles with Assertio Therapeutics, Inc.
Assertio Therapeutics Announces Exchange Offer of $200 Million of its Currently Outstanding 2.50% Convertible Notes Due 2021
Assertio Therapeutics, Inc. announced it has entered into separate, privately negotiated exchange agreements with a limited number of holders of Assertio’s currently outstanding 2.50% Convertible Notes due 2021.
Assertio Therapeutics to Report Second Quarter 2019 Financial Results After The Close of Markets on Wednesday, August 7, 2019
Assertio Therapeutics, Inc. announced that it will release second quarter 2019 financial results on Wednesday, August 7, 2019, after the close of markets.
Assertio Therapeutics, Inc. reported financial results for the quarter ended March 31, 2019, and provided an update on its business performance and strategic initiatives.
Assertio therapeutics to report first quarter 2019 financial results after the close of markets on wednesday, may 8, 2019
Assertio Therapeutics, Inc. announced that it will release first quarter 2019 financial results on Wednesday, May 8, 2019, after the close of markets.
Assertio Therapeutics, Inc. announced today that James J. Galeota, Jr. has been appointed to the Company’s Board of Directors.
Assertio Therapeutics, Inc. announced that the United States Court of Appeals for the Federal Circuit has ruled in favor of Assertio with respect to the company’s patent litigation against three filers of Abbreviated New Drug Applications for the NUCYNTA® franchise.
ASSERTIO THERAPEUTICS TO REPORT FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AFTER THE CLOSE OF MARKETS ON WEDNESDAY, MARCH 6, 2019
Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2018 financial results on Wednesday, March 6, 2019, after the close of markets. Following the announcement, the Company will host a conference call beginning at 4:30 p.m. ET to discuss its results.
Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that Heather L. Mason has been appointed to the Company’s Board of Directors. Ms. Mason is a former executive vice president of Abbott Laboratories.
Assertio Therapeutics Announces FDA Notification of Acceptance for Filing of 505(b)(2) NDA for Long-acting Cosyntropin
Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that it has received notification of acceptance for filing from the U.S. Food and Drug Administration (FDA) for its 505(b)(2) New Drug Application for its injectable formulation of long-acting cosyntropin (synthetic adrenocorticotropic hormone, or ACTH).
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that it has amended its Senior Secured Credit Facility, replacing the previous fixed adjusted EBITDA covenant with a trailing 12-month debt-to-adjusted EBITDA ratio that declines over time.
Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that it has submitted to the U.S. Food and Drug Administration a 505(b)(2) New Drug Application for its novel injectable formulation of cosyntropin (synthetic adrenocorticotropic hormone, or ACTH) depot with its partner, West Therapeutic Development, LLC. The application seeks approval for the use of this product as a diagnostic drug in the screening of patients presumed to have adrenocortical insufficiency.